Skip to Menu Skip to Search Contact Us Skip to Content
US Flag

You are accessing SGS’s website from the USA.

Visit the US website instead

Stay on the global website and remember my choice

White paper thumbnail for Benefits of Integrating Full Characterization to Early Method Development - Focus on SEC-MALS

COVID-19 has highlighted the need for faster methodologies when developing new drug products. We look at how integrating the SEC-MALS method at an earlier stage in the development process will accelerate speed-to-clinic without compromising patient safety.

Today’s biologics portfolio is increasingly composed of novel molecules, such as mRNA, viral vectors, non-native proteins, and cellbased therapies. With so many novel therapeutic modalities, institutional knowledge is no longer relevant and new strategies need to be employed to meet the twin demands of speed and safety.​

Please complete the form to download your copy.

Fields marked with an asterisk (*) are mandatory.

White paper request form

Are you an SGS client?*

200 characters remaining